Akebia Therapeutics Inc
AKBA2.040USD
+0.030+1.49%
收盤 11/07, 16:00（美東）報價延遲15分鐘
536.61M總市值
虧損本益比TTM
關於 Akebia Therapeutics Inc 公司
Akebia Therapeutics, Inc. 是一家完全整合的生物製藥公司。該公司專注於開發和商業化治療藥物。該公司的產品組合和基於缺氧誘導因子 (HIF) 的產品線包括 Auryxia（檸檬酸鐵）、Vafseo（vadadustat）、AKB-9090 和 AKB-10108。Auryxia（檸檬酸鐵）是一種口服藥物，已在美國獲批並上市，用於兩種適應症：控制透析依賴性慢性腎病 (DD-CKD) 成人患者的血清磷水平，以及治療非透析依賴性慢性腎病 (NDD-CKD) 成人患者的缺鐵性貧血 (IDA)。Vafseo（vadadustat）是一種 HIF 脯氨酰羥化酶 (HIF-PH) 抑制劑，已在 36 個國家獲批用於治療因慢性腎病 (CKD) 引起的貧血。它利用第三方進行 Auryxia 的商業分銷，包括批發分銷商和某些專業藥房供應商。
Akebia Therapeutics Inc簡介
公司代碼AKBA
公司名稱Akebia Therapeutics Inc
上市日期Mar 20, 2014
CEOMr. John P. Butler
員工數量181
證券類型Ordinary Share
年結日Mar 20
公司地址245 First Street
城市CAMBRIDGE
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編02142
電話16178712098
網址https://akebia.com/
公司代碼AKBA
上市日期Mar 20, 2014
CEOMr. John P. Butler
Akebia Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.68M
-17.18%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
170.50K
+26.48%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
131.73K
+37.18%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
130.93K
+37.49%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+40.97%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
103.38K
+52.75%
Ms. Leanne M. Zumwalt
Ms. Leanne M. Zumwalt
Independent Director
Independent Director
79.40K
+81.69%
Mr. Nicholas (Nik) Grund
Mr. Nicholas (Nik) Grund
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
45.48K
-89.72%
Mr. Erik Ostrowski
Mr. Erik Ostrowski
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
--
-100.00%
Dr. Steven K. Burke, M.D.
Dr. Steven K. Burke, M.D.
Senior Vice President - Research and Development, Chief Medical Officer
Senior Vice President - Research and Development, Chief Medical Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.68M
-17.18%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
170.50K
+26.48%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
131.73K
+37.18%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
130.93K
+37.49%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+40.97%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
103.38K
+52.75%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月19日 週二
更新時間: 8月19日 週二
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
6.25%
The Vanguard Group, Inc.
5.84%
State Street Investment Management (US)
3.02%
Geode Capital Management, L.L.C.
2.29%
Alerce Investment Management, L.P.
2.17%
其他
80.43%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
6.25%
The Vanguard Group, Inc.
5.84%
State Street Investment Management (US)
3.02%
Geode Capital Management, L.L.C.
2.29%
Alerce Investment Management, L.P.
2.17%
其他
80.43%
股東類型
持股股東
佔比
Investment Advisor
17.20%
Investment Advisor/Hedge Fund
13.14%
Hedge Fund
7.04%
Research Firm
4.02%
Individual Investor
3.57%
Private Equity
2.17%
Bank and Trust
0.20%
Pension Fund
0.16%
Venture Capital
0.06%
其他
52.45%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
299
117.08M
44.16%
+9.43M
2025Q2
284
112.41M
42.78%
+33.09M
2025Q1
280
111.54M
42.50%
+30.68M
2024Q4
258
78.54M
36.08%
+7.41M
2024Q3
257
64.16M
30.51%
-2.18M
2024Q2
248
61.31M
29.27%
-7.52M
2024Q1
290
61.37M
29.36%
-12.30M
2023Q4
289
58.79M
31.24%
-20.79M
2023Q3
300
57.28M
30.45%
-25.18M
2023Q2
308
56.18M
30.22%
-26.52M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
16.58M
6.25%
+2.61M
+18.71%
Jun 30, 2025
The Vanguard Group, Inc.
14.61M
5.51%
+1.93M
+15.18%
Jun 30, 2025
State Street Investment Management (US)
8.00M
3.02%
+1.19M
+17.50%
Jun 30, 2025
Geode Capital Management, L.L.C.
6.07M
2.29%
+1.04M
+20.75%
Jun 30, 2025
Alerce Investment Management, L.P.
5.75M
2.17%
--
--
Dec 31, 2024
Satter Muneer A
5.75M
2.17%
+5.75M
--
Dec 31, 2024
Morgan Stanley & Co. LLC
4.34M
1.64%
+2.26M
+108.33%
Jun 30, 2025
Renaissance Technologies LLC
4.19M
1.58%
+188.60K
+4.71%
Jun 30, 2025
Goldman Sachs & Company, Inc.
3.53M
1.33%
+1.07M
+43.71%
Jun 30, 2025
MPM BioImpact LLC
2.89M
1.09%
+2.89M
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Invesco Biotechnology & Genome ETF
2.36%
Invesco NASDAQ Future Gen 200 ETF
0.42%
ALPS Medical Breakthroughs ETF
0.42%
SPDR S&P Biotech ETF
0.34%
Federated Hermes MDT Small Cap Core ETF
0.2%
Direxion Daily S&P Biotech Bull 3X Shares
0.18%
iShares Micro-Cap ETF
0.13%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
Fidelity Enhanced Small Cap ETF
0.09%
查看更多
Invesco Biotechnology & Genome ETF
佔比2.36%
Invesco NASDAQ Future Gen 200 ETF
佔比0.42%
ALPS Medical Breakthroughs ETF
佔比0.42%
SPDR S&P Biotech ETF
佔比0.34%
Federated Hermes MDT Small Cap Core ETF
佔比0.2%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.18%
iShares Micro-Cap ETF
佔比0.13%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.11%
Vanguard US Momentum Factor ETF
佔比0.1%
Fidelity Enhanced Small Cap ETF
佔比0.09%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
